Secondcell Bio Publishes Biotechnology for Improved Drug Discovery Originating from The Rockefeller University
Retrieved on:
Wednesday, September 15, 2021
Library, Rockefeller University, Garbage, United States Air Force Scientific Advisory Board, Gene, Scientist, MiR-132, NOAAS Oregon II (R 332), Nobel Prize, United Airlines Flight 232, Time, Research, Springer Nature, Biology, Plasmid, Pressure, Gene expression, GABAA, CHO, Epithelium, Kaay Raav Tumhi, CFTR, Biotechnology Letters, RNA transfection, Sickle cell disease, Chromosome, CRISPR, Investment, Cell, Biotechnology, Drug discovery, FDA, Genetic engineering, Neuron, A-DNA, G protein-coupled receptor, Subtypes of HIV, Technology, DNA, MCS, Abstract, Membrane protein, HEK, Chromolithography, RNA, Zinc finger protein 532, Goal, Method, Cell engineering, Efficiency, Phajo Drugom Zhigpo, LLC, Epistasis, GPCR, Multiple, Industry, Partnership, Disease, Flow cytometry, Scale, Forestry, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics
"Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
Key Points:
- "Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
- Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.
- This work was performed by Chromocell Corporation, a biotechnology company spun out of The Rockefeller University based upon the technology.
- Secondcell, Secondcell Bio, Cellbrary, Cellbraries, Chromo-Plasmid, pChromo-Plasmid, Chromo-Tag, Drugomics, Drug Discovery at Scale, and the Secondcell Bio logo are trademarks of Secondcell Bio, LLC.